Composition and Methods of Multi-Targeted siRNA Cocktail for Treatment of Glioblastoma Multiforme
Patent Number: US8541568B2
Executive Summary:
General Description:
Uses siRNA molecules to suppress multiple oncogenic genes within glioblastoma cells, including EGFR, VEGF, and MGMT. siRNA can be administered with a pharmacologic carrier and targeted to glioblastoma cells specifically using distinct ligands. Targeting a broad array of molecules may lead to increased likelihood of therapeutic success.
Scientific Progress:
Successful in mouse models.
Future Directions:
Strengths:
Weaknesses:
Patent Status:
Legal status: Granted
Publication PMID: 19777070, 22684456
Publications:
Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol. 2009 Apr 8;3:39-52.
Wortham M, Yan H. Apples to origins: identifying brain tumor stem cell genes by comparing transcriptomes of normal and cancer stem cells. Cancer Discov. 2012;2(6):492-4.
Inventor Bio: Hai Yan
https://medschool.duke.edu/about-us/our-faculty/hai-yan
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Granted
- Patent Link: https://patents.google.com/patent/US8541568B2
- Related Patent Link: https://patents.google.com/patent/WO2017066557
- Research Institute: Duke University
- Disease Focus: Gliomas, including Glioblastoma
- Basis of Invention: Suppress oncogenic genes within glioblastoma cells using small interfering RNA (siRNA)
- How it works: siRNA can be delivered with a pharmaceutical carrier to suppress multiple oncogenic genes within glioblastoma cells. This modality may help elicit tumoricidal effects and cause glioblastoma cells to respond to conventional treatments
- Lead Challenge Inventor: Hai Yan
- Inventors: Darell Bigner, Patrick Lu, Hai Yan
- Development Stage: Preclinical
- Novelty:
- Usage of siRNA to suppress oncogenic genes using glioblastoma cell-focused ligands
- Targets multiple mechanisms involved in glioblastoma viability
- Clinical Applications:
- Targeting oncogenic proteins EGFR, VEGF, and/or MGMT in glioblastoma and non-glioma tumors in order to make the tumors vulnerable to chemotherapy
General Description:
Uses siRNA molecules to suppress multiple oncogenic genes within glioblastoma cells, including EGFR, VEGF, and MGMT. siRNA can be administered with a pharmacologic carrier and targeted to glioblastoma cells specifically using distinct ligands. Targeting a broad array of molecules may lead to increased likelihood of therapeutic success.
Scientific Progress:
Successful in mouse models.
Future Directions:
- Clinical validation
Strengths:
- Targets multiple mechanisms leading to glioblastoma validity: proliferation, angiogenesis, and chemotherapeutic resistance
- Focuses on molecular heterogeneity of glioblastoma tumors
Weaknesses:
- Not yet tested in humans
Patent Status:
Legal status: Granted
- Priority date: 2008-05-24
- Filing date: 2009-05-26
- Publication date: 2013-09-24
- Grant date: 2013-09-24
Publication PMID: 19777070, 22684456
Publications:
Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C. Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol. 2009 Apr 8;3:39-52.
Wortham M, Yan H. Apples to origins: identifying brain tumor stem cell genes by comparing transcriptomes of normal and cancer stem cells. Cancer Discov. 2012;2(6):492-4.
Inventor Bio: Hai Yan
https://medschool.duke.edu/about-us/our-faculty/hai-yan
